Why is Medicamen Biotec falling/rising?

As of 04-Sep, Medicamen Biotech Ltd is experiencing a decline in its stock price, currently at Rs 346.30, which reflects a decrease of Rs 3.7 or 1.06%. The stock has underperformed its sector by 0.91% today and is trading close to its 52-week low, just 1.47% away from Rs 341.2. Over the past week, the stock has decreased by 1.04%, and its performance over the last month shows a significant drop of 9.25%. Despite a rise in profits by 28.3% over the past year, the stock has generated a return of -18.56%, indicating poor long-term growth with an annual operating profit decline of 12.66% over the last five years. Additionally, the stock is trading below all key moving averages, and there has been a notable decrease in investor participation, with delivery volume falling by 54.65% against the five-day average.
In the broader market context, the Sensex has shown a positive return of 0.80% over the past week, contrasting with Medicamen Biotech's decline. The stock's consistent underperformance against the benchmark over the last three years, coupled with a significant drop in its value year-to-date of 32.00%, highlights a troubling trend for investors. While the company has a low debt-to-equity ratio and is trading at a discount compared to its peers, the overall sentiment remains negative due to its flat results and low return on capital employed. This combination of factors contributes to the stock's current downward trajectory in a market that is otherwise showing some resilience.